Mandate

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RevolutionRace on Nasdaq Stockholm

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RVRC Holding AB (publ) on Nasdaq Stockholm.

The offering price was SEK 75 per share, corresponding to a market value of for all outstanding shares in RevolutionRace of approximately SEK 8,469 million. Provided that the over-allotment option is exercised in full, the offering will comprise 37,784,094 shares or approximately SEK 2,834 million.

RevolutionRace offers high quality functional clothing for people with an active lifestyle. The company was founded in 2013 by Pernilla Nyrensten, CEO and Niclas Nyrensten, Creative Director. Since its inception, the founders have had the goal of creating multifunctional clothing with great fit, in the highest quality and at reasonable prices under the tag line "Nature is our playground". By selling clothes online, directly to consumers without unnecessary intermediaries, RevolutionRace can offer products that have an unbeatable value in terms of price, quality and design. Together with its customers, the company has grown rapidly and is selling its products to more than 35 countries.

Vinge’s team consisted of David Andersson, Rikard Lindahl and Anders Sundin Lundberg.

 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026